Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study is a prospective non-randomized controlled study. The purpose of this study is to
evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization
(TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after
radical surgery.